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Summary 
In experimental autoimmune encephalomyelitis (EAE) 
induced with myelin proteolipid protein (PLP) peptide 
139-151, we have previously shown that the dlsease 
is mediated by Thl cells, which recognize tryptophan 
144 as the primary TCR contact point. Here we de- 
scribe an altered peptide ligand (APL), generated by 
a single amino acid substitution (tryptophan to gluta- 
mine) at position 144 (Q144), which inhibits the devel- 
opment of EAE induced with the native PLP 139-151 
peptide (W144). We show that the APL induces T cells 
that are cross-reactive with the native peptide and that 
these cells produce Th2 (IL-4 and IL-lo) and ThO (IFNy 
and IL-lo) cytokfnes. Adoptive transfer of T cell lines 
generated with the APL confer protection from EAE. 
These data show that changing a single amino acid in 
an antigenic peptide can significantly influence T cell 
differentiation and suggest that immune deviation may 
be one of the mechanisms by which APLs can inhibit 
an autoimmune disease. 
Introduction 
The paradigm of T helper cell differentiation from naive 
precursors into type 1 helper T cells (Thl) and Th2 cells 
has proven to be a powerful tool in understanding the out- 
come of host responses to infection and autoimmune dis- 
eases (Powrie and Coffman, 1993). Naive CD4+T lympho- 
cytes triggered by antigen differentiate into at least two 
subpopulations, each producing its own set of cytokines 
and mediating distinct effector functions. Thl cells pro- 
duce interleukin 2 (IL-2) tumor necrosis factor-8, and inter- 
feron? (IFNy), activate macrophages, and induce delayed 
type hypersensitivity (DTH) responses. Th2 cells produce 
IL-4, IL-5, and IL-lo, stimulate the production of mast cells, 
eosinophils, and immunoglobulin E (IgE) antibodies, and 
regulate cell-mediated immunity (Mosmann and Coffman, 
kurrent address: Department of Medicine, University of Queensland, 
HERSTON Q4029, Australia. 
1989). IL-4 and IFNy show reciprocal inhibition and IL-10 
inhibits the production of IFNy and other Thl cytokines 
by interfering with antigen presentation by macrophages 
(Paul and Seder, 1994). These two cell populations cross- 
regulate one another because their respective cytokines 
act antagonistically (Swain, 1993; Street and Mosmann, 
1994). 
The autoreactive T cells that induce organ-specific auto- 
immune diseases including experimental autoimmune en- 
cephalomyelitis (EAE) generally display a Thl phenotype 
(Miller and Karpus, 1994). We (Kuchroo et al., 1992) and 
others (Ben-Nun and Cohen, 1982; Zamvil and Steinman, 
1990; Baron et al., 1993) have generated T cell clones 
specific for different encephalitogenic epitopes of the my- 
elin antigens, myelin basic protein (MBP), or myelin pro- 
teolipid protein (PLP). The adoptive transfer of these my- 
elin antigen-reactive Thl but not Th2 cells can induce 
EAE. In addition, during progression of EAE, Thl cyto- 
kines are present in the inflammatory EAE lesions in the 
CNS, whereas Th2 cytokines are absent, strongly sug- 
gesting that Thl cytokines play a role in the pathogenesis 
of the disease (Khoury et al., 1992; Merrill et al., 1992). 
On the other hand, regulatory T cells that suppress the 
development of EAE produce cytokines that correspond 
to the Th2 profile (Karpus et al., 1992; Chen et al., 1994) 
and recovery from EAE in mice and rats is associated with 
an increase in the presence of Th2 cells and cytokines in 
theCNS(Khouryetal., 1992; Kennedyet al., 1992). These 
findings, along with the observation that Th2 cytokinescan 
inhibit the actions of inflammatory Thl cytokines, suggest 
that the induction and activation of Th2 cells may poten- 
tially prevent EAE and other autoimmune diseases medi- 
ated byTh1 cells. Indeed, Racke et al. (1994) have recently 
shown that cytokine-induced immune deviation can be 
used as a therapy in inflammatory autoimmune diseases, 
which supports this hypothesis. To generate Th2 re- 
sponses, they administered IL-4 to animals that were im- 
munized for the development of EAE. This treatment re- 
sulted in amelioration of clinical disease, the induction of 
MBP-specific Th2 cells, and the inhibition of proinflamma- 
tory cytokines in the CNS. 
Human T cells elaborating either Thl or Th2 type cyto- 
kines have also been described, and it has been proposed 
that in leprosy, AIDS, and other human diseases these 
subtypes may affect the clinical outcome of disease (Sal- 
game et al., 1991; Romagnani, 1994; Mosmann, 1994). 
Because of the importance of Th differentiation in a num- 
ber of diseases, considerable effort is being devoted to 
elucidating the factors that influence the process. In a trans- 
genie model of spontaneous autoimmune disease, non- 
major histocompatibility complex (MHC)-encoded genes 
influence T cell differentiation and this correlated with the 
susceptibility or resistance to disease (Scott et al., 1994). 
Similarly, in murine models of Leishmaniasis, the elabora- 
tion of IL-4 or IFNr in mice of different genetic backgrounds 
correlates with disease progression or resolution (Reed 
and Scott, 1993; Belosovic et al., 1989; Sadick et al., 
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1990). A variety of experimental models have shown that 
the production of IL-12 by macrophages and IFNy by natu- 
ral killer cells promotes the differentiation of naive T cells 
into Thl cells and inhibits their differentiation into Th2 
cells. Conversely, IL-4 is necessary for Th2 differentiation 
and inhibits the development of IFNy-secreting cells 
(Hsieh et al., 1993; Paul and Seder, 1994). The route of 
administration of antigen also influences T cell differentia- 
tion and the outcome of disease. In a mouse model of 
EAE, oral administration of MBP leads to the generation 
of Th2 cells and these animals are resistant to the develop- 
ment of disease (Chen et al., 1994). Finally, the concentra- 
tion of peptide antigen has been shown to affect the type 
of immune response, suggesting that ligand density may 
have a role in determining the outcome of differentiation 
(Murray et al., 1992). In an extension of these studies, it 
has been shown that following immunization with a human 
collagen IV peptide or altered peptides derived from it, 
IL-4 mRNA is detectable by polymerase chain reaction 
(PCR) after activation of CD4+ Tcells derived from animals 
immunized with the altered peptide ligand (APL), but not 
following activation of CD4+T cells from animals immu- 
nized with the native peptide (Pfeiffer et al., 1995). 
To investigate whether antigen structure could alter T 
cell differentiation, and affect the development of an auto- 
immune disease, we have used a well-characterized auto- 
immune model in which SJL mice (H-2’) immunized with 
PLP 139-l 51 (W144) in complete Freund’s adjuvant (CFA) 
develop EAE (Sobel et al., 1994). Immunization with this 
peptide generates PLP-specific Thl cells, which can in- 
duce EAE when transferred into naive animals. The dis- 
ease differs from that caused by MBP in that the PLP 139- 
151-specific T cell clones show a greater diversity of T 
cell receptor (TCR) usage (Kuchroo et al., 1994a). Despite 
this diversity, the majority of T cell clones recognize the 
peptide in the same way, with tryptophan (W) at position 
144 as the primary TCR contact residue, and histidine 
(H147) and leucine (L141) as the secondary residues 
(Kuchroo et al., 1994b). Since W144 is the critical residue 
for normal recognition of the peptide, we made a large 
panel of peptides with single amino acid substitutions at 
this position. A peptide in which the tryptophan was 
changed to glutamine (Q144) induced a T cell response, 
which was strikingly different from that induced by the 
native peptide and also prevented the development of EAE 
induced by the native peptide. 
Results 
The APL Q144 Protects Mice from EAE 
To determine whether the altered peptide itself can induce 
EAE, animals were immunized with Q144 in CFA. No clini- 
cal disease was detected up to 42 days following immuni- 
zation with this peptide, although all animals concurrently 
immunized with the native peptide, as expected, devel- 
oped severe EAE (data not shown). We next investigated 
whether coimmunization of Q144 peptide with the native 
PLP 139-151 would affect the induction of EAE. Results 
from a representative experiment (Figure 1) show that 
5 10 15 20 25 30 35 40 
Day 
Figure 1. Coimmunization with 0144 Ameliorates EAE 
Animals were immunized with the native peptide W144 alone (open 
circles) or coimmunized with W144 and Q144 at a ratio of 1:5 (open 
squares) and assessed daily for signs of clinical disease. 
coimmunization of altered peptide with the native peptide 
reduced the incidence and mean severity of disease. The 
effect of the altered peptide on EAE was then tested in a 
larger series of experiments in which Q144 was either 
given before (preimmunization) or together with (coim- 
munization) the encephalitogenic PLP 139-151 peptide. 
The results show that most of the animals (about 70%) 
preimmunized with Q144 were protected from disease and 
in those animals that became sick there was a significant 
reduction in the clinical disease (Table 1). The mean day 
of onset of disease was later in the group preimmunized 
with Q144 than in the control group (no preimmunization) 
or animals immunized with L144or T144. Coimmunization 
of Q144 with the native peptide (W144) also protected 
animals from disease (5 of lo), decreased disease sever- 
ity but did not delay disease onset, and in the mice that 
did have clinical signs reduced the amount of CNS inflam- 
mation. 
The Peptide (2144 Is Not an MHC Blocker but 
Induces T Cells that Are Cross-Reactive 
with the Native Peptide 
A number of studies have shown that unrelated synthetic 
peptides or altered self-peptides may bind to MHC class II 
molecules more efficiently than the autoantigenic peptide 
inhibiting its binding and preventing the development 
of autoimmune disease (Lamont et al., 1990). To study 
whether Q144 functions by a similar mechanism, we 
tested the lymph node cells (LNCs) from SJL mice immu- 
nized with Q144, the native PLP 139-151 peptide, or a 
mixture of both for in vitro proliferative responses against 
various antigens (Figure 2). The LNCs from animals immu- 
nized with the native peptide proliferated in vitro to the 
immunogen but not to a control PLP peptide (PLP 190- 
209) or to other peptides with a single substitution at posi- 
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Table I. Immunization with Altered Peptide Ligands Protects Mice from EAE 
Peptide 
Preimmunized Immunized 
Clinical Disease 
Mean day of 
Incidence onset 
Mean maximum 
severity 
Histological Disease: Number of 
Inflammatory Lesions 
With clinical Without clinical 
disease (n) disease (n) 
Preimmunization 
None 
cl144 
L144 
T144 
Coimmunization 
None 
None 
None 
None 
w144 
w144 
WI44 
w144 
w144 
Cl144 
w144 + cl144 
(1:5) 
w144 + L144 
(1:5) 
13113 15.1 + 1.4 3.3 + 0.3 74*25(4) - 
4113” 23.6 f 6.5 2.3 f 0.F 61 (1) 1152 (3) 
417 16.0 f 1.3 3.2 + 0.6 13626 (3) 24 (1) 
414 14.5 f 0.5 2.3 f 0.5 35 f lO(4) - 
9110 
0114 
4110” 
415 
10.3 f 0.2 4.4 f 0.5 100 + 25(5) ND 
- ND 
12.0 f 0.6 2.1 * 0.45 7 (1) 1 f 0.5 (4) 
12.5 + 0.3 2.1 f 0.4’ 37 * 8 (4) 0 (1) 
a p < 0.001 
b p < 0.05 by Fisher’s exact probability test (compared with controls) 
c p < 0.001 by t test (compared with controls) 
EAE was induced in SJL mice by immunization with W144 (native PLP 139-151) emulsified in CFA as described. Mice were preimmunized with 
100 pg of altered peptide emulsififed in CFA 20-40 days prior to the induction of disease or coimmunized with W144 and the altered peptide at 
the ratio shown. ND, not determined. 
tion 144 (Cl144 or Al 44), or a peptide with a double substi- and to a mixture of native peptide and Q144, but the re- 
tution at positions 144 and 147 (L144M147). In contrast, sponse to Q144 alone was reduced. These data suggest 
LNCs from animals immunized with Q144 showed a much that the Q144 peptide does not inhibit the generation of 
more degenerate response in that they proliferated to the T cells specific for the native PLP peptide. Coimmunization 
same extent when stimulated in vitro with the native pep- of the native peptide with Ql44, however, lowers the T 
tide W144 or Q144, and responded even more vigorously cell responses specific for Q144. This may be due to com- 
to a mixture of native peptide and Q144. When animals petition for I-A* binding during the initial T cell induction, 
were immunized with the native peptide and Q144 pep- since the native W144 peptide binds to I-AS more efficiently 
tides together, the LNCs responded well both to W144 than does Q144 (Kuchroo et al., 1994b). 
IO 100 IO’ 102 10’ 100 IO 10’10’ 100 IO’ 102 
Antigen concentration @ml 
. PLP 139-151 A L,44,R,47 l PLP 190209 
n 0144 . A144 0 PLP139.15, to144 
Figure 2. Proliferative Response of LNC from Mice Immunized with 
W144. Q144. or W144 plus Q144 
Mice were immunized with WI44 (a), Q144 (b), or W144 plus Q144 (c). 
LNCs were stimulated in vitro 10 days following immunization with the 
antigens indicated. Mice immunized with a single peptide received a 
total of 100 ug of antigen: mice immunized with a mixture of PLP 139- 
151 and Q144 received 100 pg of native peptide and either 100 kg 
or 300 ug of Q144. There were no significant differences when the 
peptides were used at either of these ratios and the data are pooled 
in (c). In these experiments, when a mixture of peptides was used 
to activate LNCs the total peptide concentration was the sum of the 
individual peptide concentrations. The results are expressed as a stim- 
ulation index (SI) defined as mean cpm with antigen/mean cpm with 
medium alone. The results shown are the average SI of three to five 
independent experiments. 
Immunization with Q144 Alters the Pattern 
of Cytokine Production 
To compare the type of T cell response generated in mice 
immunized with Q144 with that induced by the native pep- 
tide, the cytokines elaborated by LNCs taken from these 
animals 10 days after immunization were measured (Table 
2). LNCs from animals immunized with native W144 pep- 
tide proliferated and produced significant amounts of IL-2 
and IFNy in vitro when stimulated with the native peptide 
but not when stimulated with Q144 or A144. This Thl pat- 
tern of cytokine production is consistent with the pattern 
of response seen in T cell clones derived from mice immu- 
nizedwithW144(Kuchrooetal., 1993),andwiththe known 
effects of CFA upon the outcome of T cell differentiation 
(Janeway et al., 1988). In contrast, LNCs from animals 
immunized with Q144 proliferated quite vigorously when 
activated with either Q144, native W144, or A144. When 
these LNCs were activated by Q144, significant levels of 
IL-2, IFNy, and IL-10 were detected. IL-4 was measured 
by enzyme-linked immunosorbent assay (ELISA) or using 
CT4S cells and was less than 2 x background in all assays. 
The data suggests that immunization with Q144 alters the 
phenotype of the T cells induced, leading to cells produc- 
ing IL-10 in addition to cells producing IL-2 and IFNy. 
To determine the type of cells involved in the antigen- 
specific proliferation and production of various cytokines 
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Table 2. Cytokine Production by Lymph Node Cells from Mice Immunized with the Native Peptide W144 or the Altered Peptide 0144 
Antibody Treatment 
Control Anti-CD4 
w/ml w/ml 
Immunization Activation ACPM IL-2 IFN y IL-10 ACPM IL-2 IFN y IL-10 
w144 w144 109 100 170 4250 75 13 300 <50 1300 <50 
0144 13 900 60 260 60 4000 <50 380 <50 
w144 + Q144 84 500 70 1030 <50 12 300 <50 600 <50 
Al44 6600 <50 <IO0 <50 3500 <50 270 <50 
p190 300 <50 <lOO <50 3800 <50 240 <50 
w144 21 300 <50 270 <50 5700 <50 260 <50 
0144 91 300 150 4450 160 32 300 <50 1270 <50 
w144 + Q144 03 400 120 2760 140 23 200 <50 1300 <50 
Al44 21 100 <50 <IO0 60 4600 <50 170 <50 
p190 0 <50 170 <50 1500 <50 <lOO <50 
Groups of SJL mice were immunized with 100 uglmouse of either the native W144 peptide or Q144 in CFA. LNCs were harvested 10 days after 
immunization and activated with lo-50 pg/ml of the relevant peptide in the presence of control antibody (KJ-18) or anti-CD4 antibody (GK1.5). 
When peptides were mixed, the total peptide concentration was kept constant and the ratio of peptides was 1:l. Supernatants were collected 24 
and 40 hr after activation and cytokine concentrations were determined as described. Values >3x baseline are highlighted, One representative 
a144 
experiment of four is shown. 
- 
following in vivo immunization with the altered peptide 
Q144, monoclonal antibodies (MAbs) specific for anti- 
CD4, anti-CD& and anti-TCR V38.1N68.2 (as an isotype- 
matched control antibody) were added to the LNC at the 
time of in vitro activation. Data with the control anti-Vf38.11 
Vf38.2 MAb and anti-CD4 antibody are shown (Table 2), the 
results obtained with the anti-CD8 antibody were similar to 
the control MAb (data not shown). In the LNCs taken from 
mice immunized with the native PLP peptide there was a 
dramatic inhibition (88%) of proliferation and IFNy produc- 
tion in the presence of anti-CD4 MAb. In the LNCs from 
mice immunized with the altered peptide Q144 and acti- 
vated with Cl144 peptide, addition of anti-CD4 antibody 
inhibited proliferation by65% and IFNy production by over 
70%. IL-2 and IL-10 were completely inhibited by anti-CD4 
antibody. These data suggest that the immune deviation 
(with increase in IL-10 production) mediated by the altered 
peptide 0144 is dependent upon the antigen-specific acti- 
vation of CD4’ helper/inducer T cells. 
T Cells Specific for Q144 Cross-React with the 
Native Peptide and Produce ThO or 
Th2 Cytokines 
To analyze the cells induced by Q144 further, T cell lines 
were generated from SJL mice immunized with W144 or 
Q144. A T cell line derived from animals immunized with 
native peptide W144 (WL.l) has properties that recapitu- 
late those found in primary LNC cultures, with a dominant 
proliferative response to W144 and production of the Thl 
cytokine IFNy (Figure 3). The T cell line WL.l also pro- 
duced IFNy upon activation with the altered peptides Q144 
and Al44 and, in some experiments, low levels of IL-10 
were detected when the line was stimulated with Q144. 
The Tcell line derived from animals immunized with Q144 
(QL.l) demonstrated greater cross-reactivity in that it 
showed a significant proliferative response to the Q144, 
native, and Al44 peptides and lower responses to the 
L144/R147 peptide (Figure 3), but showed no response 
to an unrelated PLP peptide (data not shown). The line 
produced high levels of both IFNy and IL-10 in response 
to these antigens. 
To analyze whether IL-10 and IFNy were produced by 
the same cell, the Q144specific T cell line (QL.l) was 
cloned by limiting dilution and screened for cytokine pro- 
duction (Figure 4). Of the 48 clones that were established, 
27 produced significant levels of cytokine following activa- 
tion with Q144. IL-10 was the commonest cytokine de- 
tected, produced by 22 of 27 (81%) clones. Nine clones 
produced only IL-lo, five produced IL-4 and IL-lo, four 
n IFN-T 
q IL-10 
w a LR A w a LR i 
Stimulating Antigen 
Figure 3. Proliferative Response and Cytokine Production by T Cell 
Lines Specific for native W144 (WL.1) or 0144 (QL.1) Peptides 
(a, b) Proliferative response. 
(c, d) Cytokine production. 
The T cell lines were activated with various antigens (50 Fglml): W 
(W144, the native peptide), Cl (Q144), LR (L144/R147), and A (A144). 
The proliferative response was measured in triplicate and expressed 
as a mean stimulation index calculated as described in Figure 2. Cyto- 
kine concentrations in culture supernatants taken at 40 hr were mea- 
sured by ELISA. 
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Figure 4. T Cell Clones Specific for 0144 are Th2- and ThO-Like 
Clones (48) derived from CL.1 were activated with 20 uglml of Q144. 
The supernatants from the clones were taken at 40 hr and tested for the 
production of Thl (IFNT) and Th2 (IL-l 0, IL-4) cytokines. The amount of 
cytokine produced by each clone is displayed in terms of IFNy versus 
IL-IO and IL-4 versus IL-10 to determine whether the Q144specific 
clones were of ThO (IFNy. IL-lo) or Th2 (11-4, IL-lo) phenotype. The 
righthand panel shows that 9 clones made high levels of IL-4. Of these, 
7 were classified as Th2 and 2 as ThO. The lefthand panel shows that 
7 clones secreted IL-10 and IFNy together. Of these, 3 also secreted 
other cytokines. 
produced IL-10 and IFNr, and four clones produced a mix- 
ture of three or four cytokines (IL-lo, IL-4, IL-2, and IFNy). 
Of the remaining five clones, three produced only IFNy, 
one produced IL-2, and one produced IL-4. These results 
clearly show that immunization with the APL has resulted 
in the development of predominantly ThPlThO ceils pro- 
ducing high levels of IL-4 and IL-lo, and in the generation 
of a population of cells simultaneously secreting IL-10 and 
IFNr. A panel of 16 Q144specific T cell clones was se- 
lected at random and tested for cross-reactivity to the na- 
tive W144 peptide. As assessed by T cell proliferation 
assay 44% (7 of 16) of these Q144 specific T cell clones 
cross-reacted with W144 (data not shown). 
T Cell Lines Induced by Q144 Protect Mice 
from EAE 
To determine whether T cells induced by immunization 
with Q144 were able to transfer protection, naive SJL mice 
were immunized with either W144, Q144, or a nonenceph- 
alitogenic peptide PLP 190-209. Short-term T cell lines 
were generated from LNCs prepared from mice 10 days 
after immunization and activated in vitro with immunizing 
or control peptides. LNCsfrom mice immunized with W144 
and Q144 were also activated with Q144 and W144, re- 
spectively, to generate cross-reactive T cell lines. After 4 
days in culture, T cell blasts were harvested and trans- 
ferred into naive mice, which were then actively immu- 
nized with W144lCFA to induce EAE. The course of the 
disease was followed for 26 days (Figure 5). As a positive 
control, mice preimmunized with Q144 were further immu- 
nized with PLP 139-151 and followed for disease progres- 
sion in the same experiment. 
Transfer of T cell lines generated from the LNCs of mice 
immunized with native W144 and activated with W144 
(data not shown) or Q144 accelerated the onset of clinical 
disease by l-2 days and enhanced the maximum disease 
severity when compared with the control mice that were 
0 5 10 15 20 25 30 
Figure 5. Transfer of Protection by Short-Term T Cell Lines 
SJL mice were immunized with W144,0144, or PLP 190-209 in CFA. 
LNC were harvested 10 days later and activated in vitro with 20 ugl 
ml of the relevant peptide. Live cells were purified 4 days after activa- 
tion by Ficoll-Hypaque centrifugation, resuspended in phosphate- 
buffered saline, and transferred into naive mice as described. Mice 
were simultaneously immunized with PLP 139-1511CFA for disease. 
The results presented are the mean disease scores of each group 
from three independent experiments. 
injected with a T cell line specific for an unrelated PLP 
peptide 190-209. In contrast, the T cell lines generated 
from mice immunized with Q144 and activated in vitro with 
Q144 conferred some protection from clinical disease but 
the greatest protection was seen after transfer of the T 
cell line generated from mice immunized with Q144 and 
activated in vitro with W144. This demonstrates that immu- 
nization with Q144 induces cells that protect mice from 
EAE, but that these T cells are cross-reactive and need 
to be activated by the native peptide to mediate protection. 
Discussion 
We have shown that immunization with an autoantigenic 
peptide altered at the primary TCR contact point (Q144) 
protects mice from the development of EAE. This protec- 
tion is not due to MHC blockade. Rather, immunization 
with the altered peptide induces T cells of a ThO and Th2 
phenotype. Furthermore, theT cellsgenerated byimmuni- 
zation with the altered peptide are degenerate in their rec- 
ognition in that they are activated by not only the immuniz- 
ing antigen (Q144) but also the native peptide W144 and 
several analogs of this peptide. The transfer of short-term 
lines derived from mice immunized with the altered pep- 
tide protects animals from the induction of disease by the 
native peptide. Although APLs have been shown to have 
multiple functions, including induction of anergy, TCR an- 
tagonism and partial activation (Evavold et al., 1993; Sette 
et al., 1994) our datasuggest that APLscan also influence 
T cell differentiation and thereby affect the overall disease 
course. 
Mechanism by which Unrelated Synthetic Peptides 
or Altered Self-Peptides Inhibit Development 
of Autoimmune Diseases 
A number of studies have shown that some peptides can 
prevent the development of autoimmune disease by MHC 
blockade. These peptides compete with self-peptides for 
binding to MHC class II molecule(s) and inhibit disease 
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(Lamont et al., 1990; Sakai et al., 1989). Several lines of 
evidence show that Cl144 does not inhibit the generation 
of W144-specific T cells, and suggest that the Q144 does 
not inhibit disease in vivo by MHC blockade. First, preim- 
munization of mice with Q144, 4-8 weeks prior to the im- 
munization with the native peptide prevents EAE. Second, 
transfer of T lines that are derived from mice immunized 
with Q144 only and then activated in vitro with W144 (con- 
ditions under which there is no chance of MHC blockade) 
transfer protection (Figure 5). Third, the relative binding 
affinity of Q144 and W144 to I-As is not significantly differ- 
ent (Kuchroo et al., 1994b). And fourth, in vitro, LNCs from 
animals immunized with W144 plus Q144 are activated 
almost equally by W144 alone or a mixture of W144 and 
Q144 (Table 2). 
Analogs of disease-inducing self-peptides have been 
demonstrated to inhibit the disease process in Several ex- 
perimental autoimmune diseases (Gautam et al., 1992; 
Wauben et al., 1994). These analogs are structurally simi- 
lar to the native peptide and MHC blockade is not the Only 
mechanism responsible for disease inhibition (Janeway, 
1989; Wauben et al., 1992). A number of peptide analogs 
that inhibit clinical disease have been described but the 
actual mechanism(s) contributing to the inhibition of dis- 
ease have been difficult to define (Wraith et al., 1989; 
Smileketal., 1991). Ourdataofferan explanation forthese 
results and suggest that some peptide analogs may medi- 
ate their protective effects by immune deviation. 
Recently, it has been demonstrated that both modifica- 
tion of antigenic peptides at TCR contact points (Evavold 
et al., 1993) and subtle changes in MHC molecules (Raci- 
oppi et al., 1993) can generate altered TCR ligands that 
have multiple functions. Some of the peptide analogs are 
capable of binding to the TCR but are incapable of trig- 
gering a response and thus act as pharmacological antag- 
onists (TCR antagonists) (De Magistris et al., 1992; Kuch- 
roo et al., 1994b; Franc0 et al., 1994); some may interact 
with the TCR and anergize the responding cells (Sloan- 
Lancaster et al., 1993); and some analogs have been 
shown to activate T cells partially (Evavold and Allen, 
1991). These studies indicate that an altered TCR ligand 
can interact with the TCR and induce changes in the re- 
sponding cells without evoking a full repertoire of effector 
functions. Our results suggest that the Q144 peptide does 
not act as an MHC blocker and does not have TCR antago- 
nist activity (data not shown). Instead, this APL affects T 
cell differentiation in vivo and induces T cells that are of 
a ThO or Th2 phenotype rather than autoaggressive dis- 
ease-inducing Thl cells. Although IL-4 protein is undetect- 
able in the primary culture, cells secreting IL-4 may be 
present in the mixed population that responds to Q144, 
but remain inhibited in their expression of cytokine by the 
high concentration of IFNT. This implies that analogs 
themselves may regulate immune responses and adds a 
novel mechanism by which the altered self-peptides may 
function in vivo. 
Role of Antigen in T Cell Differentiation 
T cell differentiation is a complex process that is known 
to be influenced by the microenvironment. Cytokines are 
clearly an important part of this milieu but other factors 
may also have a role (Scott et al., 1994; Kuchroo et al., 
1995). In the present experiments, we have demonstrated 
that the alteration of a single amino acid leads to a change 
in the phenotype of the responding T cell. This result is 
particularly surprising since all immunizations were car- 
ried out with peptide emulsified in CFA, an adjuvant which 
strongly favors the generation of Thl cells (Janeway et 
al., 1988). The generation of cells secreting IFNy and IL-l 0 
together may reflect the combined influence of the high 
levels of IL-12 known to be induced by mycobacteria, in 
the presence of an APL that favors the generation of Th2 
cells, since this phenotype is neither Thl nor Th2. Whether 
these cells are terminally differentiated or whether they 
represent a form of ThO cell type has yet to be established. 
The molecular mechanisms by which altered antigen 
affects T cell differentiation are unknown. Q144 binds l-As 
with approximately half the affinity of the native peptide 
(Kuchroo et al., 1994b) and substitution at position 144 
could significantly affect its ability to stabilize MHC com- 
plexes, a property which has been shown to influence im- 
munogenicity (Nelson et al., 1994). These differences 
might lead to changes in ligand density, MHC-peptide con- 
formation, or both, which could alter the pattern of cyto- 
kines secreted or the expression of adhesion and costimu- 
latory molecules by the antigen-presenting cell (APC). 
Alternatively, an APL may induce differential signaling 
through the TCR of naive T cells (Evavold et al., 1993; 
Sloan-Lancaster et al., 1994; Madrenas et al., 1995). This 
differential signaling through the TCR in vivo might lead 
to the release of cytokines (such as IL-4) from Th precursor 
cells, which act upon the T cell in an autocrine fashion, 
committing T precursor cells to a Th2 lineage even in a 
microenvironment that favors the generation of Thl cells. 
In support of our data, APLs have recently been shown 
to affect T cell differentiation and induce IL-4 mRNA in 
LNC culture, although IL-4 was not detectable in culture 
supernatant (Pfeiffer et al., 1995). Similarly, it has also 
been shown that human T cell clones may change their 
cytokine profile when activated in vitro with analogs of 
the native autoantigenic MBP peptide, providing further 
evidence of a physiological role for this process (Windha- 
gen et al., 1995). Another possibility is that the native anti- 
gen may induce qualitatively different intracellular signals 
than those elicited by the peptide analogs, leading directly 
to differences in lineage commitment. One prediction of 
this model would be that differentiation and lineage com- 
mitment can occur independently of the cytokine environ- 
ment. Several possible mechanisms have been proposed 
to explain how the TCR may transduce differential signals, 
including ligand density and conformational changes 
within the TCR itself (Janeway and Bottomly, 1994) but 
their role in T cell differentiation has not been tested. 
The APL Q144 Induces T Cells that Are Degenerate 
in their Recognition and Transfer Protection 
Immunization with Q144 produced a population of T cells 
that is more cross-reactive than the T cells induced by 
immunization with the native peptide W144. Position 144 
is the primary TCR contact point of the native peptide and 
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peptides with substitutions at this residue are not recog- 
nized by a panel of W144specific T cell clones (Kuchroo 
et al., 1994b). One explanation for the greater cross- 
reactivity of the Q144-specific cells is that they may use 
another residue as the primary TCR contact point, which 
is common between Q144 and the native peptide, and 
therefore substitutions at position 144 are tolerated. This 
would suggest that Q144-specific T cells are derived from 
different precursors than cells induced with the native pep- 
tide, since TCRs recognize a different part of the peptide. 
Alternatively, naive T cells specific for W144 and with the 
potential to become Thl cells if activated with the native 
peptide, might differentiate into ThP-like cells when acti- 
vated by Q144. Recently, attention has been drawn to 
the potential importance of cross-reactivity in maintaining 
long-term immunological memory (Matzinger, 1994) and 
the same phenomenon may be important in the develop- 
ment and regulation of autoimmune disease. 
In this study, we directly demonstrate the generation by 
immunization with Q144 of T cells that protect animals 
from EAE. Cells from animals immunized with Q144 and 
activated in vitro by W144 were the most effective in this 
regard, confirming the importance of cross-reactive T cells 
in this system. These experiments support the hypothesis 
that antigen can influence the outcome of T cell differentia- 
tion and suggest a novel mechanism by which APLs can 
protect animals from EAE. This protection arises because 
the Q144specific T cells have at least two important prop- 
erties: they cross-react with the native peptide and can 
therefore be activated by the native antigen in the CNS, 
and they secrete Th2 cytokines upon activation with either 
native or Q144 peptide. Th2 cells are known to inhibit Thl 
responses via the production of IL-4 and IL-1 0 and, more- 
over, adoptive transfer of PLP 139-l 51 -specific Th2 cells 
can protect mice from EAE (Kuchroo et al 1995). In a pre- 
liminary experiment, we have examined the effect of anti- 
IL-4 antibody on protection mediated by Q144 in vivo and 
found that this treatment abrogated protection (L. B. N. 
and V. K. K., unpublished data). This provides further sup- 
port for the hypothesis that Q144 mediates protection by 
inducing regulatory Th2 cells in vivo. The ability of altered 
peptides to modify the immune response from a patho- 
genic to a protective one may have significant implications 
for autoimmunity. In addition, the peptide analogues will 
be useful tools for studying intracellular signaling and for 
dissecting the influence of antigen on the process of T 
cell differentiation. 
Experimental Procedures 
Animals 
Female (4 to 6week-old) SJL mice were purchased from the Jackson 
Laboratory (Bar Harbor, Maine) and housed under virus-free condi- 
tions They were maintained in accordance with the guidelines of the 
Committee on Animals of Children’s Hospital and Harvard Medical 
School, Boston. 
Antigens 
Peptideantigensfor invitrostudies weresynthesized by Dr. Ft. Laursen 
on a Milligen model 9050 synthesizer using Fmoc chemistry. Milligen 
PAL amide resins were used to produce peptides with C terminal am- 
ides. Most peptides were >90% pure, as determined by high pressure 
liquid chromatography (HPLC), and were not purified further. For dis- 
ease Induction, HPLC-purified peptide PLP 139-l 51, obtained from 
Alkermeres, Incorporated (Cambridge, Massachusetts) was used in 
some experiments. The peptides used in these experiments were PLP 
139-151 (HSLGKWLGHPDKF), Q144 (HSLGKQLGHPDKF), Al44 
(HSLGKALGHPDKF), T144 (HSLGKTLGHPDKF), L144/R147 (HSLG- 
KLLGRPDKF), and PLP 190-209 (SKTSASIGSLCADARMYGVL). Sin- 
gle letter abbreviations for the amino acids are the following: A, Ala; 
C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; 
M, Met; N, Asn; P, Pro; Q, Gin; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; 
and Y, Tyr. 
lnductlon and Assessment of EAE 
Mice were injected subcutaneously at two sites with W144 emulsified 
in CFA and supplemented with Mycobacterium tuberculosis H37 RA 
(500 uglmouse; Difco, Detroit, Michigan). On day0 and 3, each mouse 
was also injected intravenously with 108 heat-killed Bordetella pertus- 
sis bacilli (pertussis vaccine lot number 264, Massachusetts Public 
Health Biological Laboratories, Boston, Massachusetts). The concen- 
tration of W144 was titrated in each set of experiments to give optimal 
disease and was between 50-100 us/mouse. In the preimmunization 
experiments, SJL mice were initially immunized at two sites with pep 
tide emulsified in CFA supplemented with M. tuberculosis H37 RA 
(400 uglmouse; Difco) or not preimmunized (controls). In the coimmun- 
ization experiments, mice were immunized with the peptide or mixture 
of peptides shown, keeping the concentration of disease-inducing pep- 
tide constant. Mice were examined daily beginning on day 9 for dis- 
ease, which was assessed clinically according to the following criteria: 
0, no disease; 1, limp tail; 2, hindlimb weakness; 3, hindlimb paralysis; 
4, hindlimb plus forelimb paralysis; 5, moribund or dead. When animals 
were moribund or at the end of the experiment (day 30-40) mice 
were sacrificed and brains and spinal cords were fixed, processed 
for histologic analysis, and evaluated as described (Kuchroo et al., 
1994b). 
Culture Media 
DMEM supplemented with 0.1 mM nonessential amino acids, sodium 
pyruvate (1 mM), L-glutamine (2 mM), MEM essential vitamin mixture 
(1 x). penicillin (100 U/ml), streptomycin (100 U/ml), gentamicin (0.1 
mglml), 10% heat-inactivated fetal bovine serum (BioWhittaker, Incor- 
porated, Walkersville, Maryland), asparagine (0.1 mM), folic acid (0.1 
mglml), and 2-mercaptoethanol (5 x 10m5 M) (Sigma, St Louis, Mis- 
souri) was used for the culture of LNCs. For the expansion of T cell 
lines and clones, this medium was supplemented with 0.6% T cell 
growth factor (T-Stim, Collaborative Biomedical Research, Bedford, 
Massachusetts) and 0.06% recombinant 11-2. 
In Vitro Proliferation Assays 
Mice were injected subcutaneously at five sites with antigen emulsified 
in CFA (Difco) containing a total of 250 ug M. tuberculosis H37 RA. 
Mice immunized with a single peptide received a total of 100 ug of 
antigen; mice immunized with a mixture of W144 and Q144 received 
100 ug of WI44 and either 100 ug or 300 ug of Cl144 (i.e., a total of 
200 or 400 ttg of antigen per mouse). On day 10, lymph nodes were 
removed and LNCs prepared from them. LNCs (4 x 105 per well) were 
cultured in triplicate in 96-well round-bottomed plates (Falcon, Becton 
Dickinson, Lincoln Park, New Jersey), in the presence of antigen, for 
46 hr and then [JH]thymidine (1 f&i/well) was added for the last 16 
hr before harvesting the cells. The PH]thymidine incorporation was 
determined in a Beckman scintillation counter (model LS 5000; Beck- 
man Instruments, Fullerton, California). The stimulation index (SI) was 
calculated as mean cpm with antigen/mean cpm with medium plus 
APCs alone. 
In Vitro Cytokine Assays 
Supernatants were collected from LNCs (4 x lo5 per well), T cell lines 
(5 x 1 04T cells plus 5 x 1 O5 syngeneic irradiated spleen cells per well) 
or T cell clones 24 or 40 hr after activation in vitro. The concentration of 
IL-4 in the supernatants of LNC was measured by ELISA or by using 
CT4S cells (a gift from Dr. A. K. Abbas), which were maintained in 
culture in medium supplemented with recombinant IL-4 Prior to assay, 
CT4S cells were kept overnight in IL-4-free medium, harvested, and 
washed three times, then resuspended at 1 x 105 cells/ml. Aliquots 
(50 @I) were dispensed into 96-well flat-bottomed plates and incubated 
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either with known concentrations of recombinant mouse IL-4 (Phar- 
mingen, San Diego, California) or supernatants from stimulated LNCs. 
After 24 hr, the plates were incubated for 16 hr with added PH]thymi- 
dine, harvested, and the radioactivity counted. Standard curves were 
derived from cells exposed to known concentrations of 11-4. 
The concentrations of IFNT, IL-2, IL-lO(and IL-4 in the supernatants 
collected from T cell lines or T cell clones) were measured by quantita- 
tive capture ELISA according to the guidelines of the manufacturers. 
In brief, purified rat MAb to mouse cytokine IL-2 (clone JES-lAlP), IL4 
(clone BVD4-1 Dl 1), IL-10 (clone JES5-2A5), and IFNy (clone R4-6A2)) 
were obtained from Pharmingen (San Diego, California) and used to 
coat ELISA plates (Immulon 4, Dynatech Laboratories, Chantilly, Vir- 
ginia). Recombinant mouse cytokines(lL-2, IL-4, IL-lo, and IFNy; Phar- 
mingen) were used to construct standard curves and biotinylated rat 
MAb to mouse cytokine IL-2 (clone JES6-5H4). IL4 (clone BVDG- 
24G2), IL-10 (clone SXC-1), and IFNy (clone XMGl.2) (Pharmingen) 
were used as the second antibody. Assays were developed with TMB 
Microwell Peroxidase Substrate (Kirkegaard and Perry Laboratories, 
Maryland) and read after the addition of stop solution at 450 nm using 
a model 2550 Microplate Reader (Bio-Rad Laboratories, California). 
Derivation of T Cell Lines and Clones 
T cell lines were generated from LNCs from mice immunized with 
W144 (WL.1) or Q144 (QL.l). LNCs were prepared and cultured in 
syngeneic serum with the appropriate antigen (20 uglml) for 5 days. 
T cell blasts were purified over a Ficoll-Hypaque gradient and fed 
with culture medium containing 0.6% T cell growth factor (T-Stim, 
Collaborative Biomedical Research) and 0.06% recombinant IL-2. 
Cells were fed every 2-3 days and restimulated every lo-16 days by 
the immunizing antigen (20 uglml) plus irradiated syngeneic spleen 
Cells (5 x lo8 cells/ml) as a source of APCs. Clones were obtained 
by culturing cells from QL.1 at limiting dilution as previously described 
(Kuchroo et al., 1992). Cells were fed with culture medium plus T 
cell growth factors every 2-3 days and restimulated with a mixture of 
antigen (20 pglml) plus irradiated syngeneic spleen cells (5 x 1 Oscells/ 
ml) after 10 days. Wells that contained growing cells were identified 4 
days later and the cells transferred to 46-well plates (Sumilon, Sumi- 
tomo Bakelite Company, Tokyo, Japan), fed with medium containing 
T cell growth factors every 2-3 days, and expanded by activation with 
antigen and APCs every 2-4 weeks. 
Adoptlve Transfer of T Cell Lines 
Mice were immunized using the same protocol as the in vitro prolifera- 
tion assays. Lymph nodes were removed on day 10 and LNCs were 
resuspended at a concentration of 6-10 x 10 cells per ml in culture 
medium containing 0.5% syngeneic serum in place of fetal bovine 
serum. Cells were cultured in the presence of various antigens (20 
uglml) for 4 days, then harvested and purified over a Ficoll-Hypaque 
gradient. Cells were resuspended in phosphate-buffered saline at 25 
x lo6 cells per ml and injected intravenously into recipient animals 
(0.2 ml, 5 x 108 cells per mouse), then recipient mice were immunized 
with the native peptide PLP 139-l 51 and CFA as described to induce 
active EAE. 
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